Undiagnosed chronic liver disease (CLD) in patients presenting with Hepatocellular Carcinoma (HCC)

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter P. Spiliopoulou
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors P. Spiliopoulou1, J. Millar1, C. Bamford2, L. Bisset1, J. Evans3
  • 1Beatson West of Scotland Cancer Center, Glasgow, United Kingdom, /
  • 2Beatson, Glasgow, United Kingdom, /
  • 3The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, /


The worldwide incidence of hepatocellular carcinoma (HCC) is increasing. The vast majority of cases occur in patients with underlying cirrhosis, and most patients present with disease that is too advanced for potentially curative resection, with or without transplantation. Consequently, European-based guidelines support screening for patients with established cirrhosis secondary to Hepatitis B (HBV), Hepatitis C (HCV), alcohol-induced liver disease (ALD), hemochromatosis (HFE) and primary biliary cirrhosis (PBC) to detect HCC at an early stage. The aim of our study was to determine the prevalence of undiagnosed CLD in patients with HCC referred to a tertiary regional cancer center in the UK, to describe the pattern of patient referrals, hepatology input prior to the diagnosis of HCC, and participation in a screening program.